Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090167 | 1.00 | SSTR4 (0.54) | SSTR4MAPK1HTTEPHX1PDK1 | |
| SCHEMBL10261560 | 0.89 | MAPK1 (0.45) | SSTR4MAPK1HTTEPHX1ALDH1A1 | |
| SCHEMBL15722037 | 0.81 | MAPK1 (0.41) | SSTR4MAPK1HTTEPHX1EPHX2 | |
| SCHEMBL3830932 | 0.81 | MAPK1 (0.41) | SSTR4MAPK1HTTEPHX1EPHX2 | |
| SCHEMBL25685634 | 0.80 | SSTR4 (0.49) | SSTR4HTTEPHX1PDK1PDK2 | |
| SCHEMBL20354508 | 0.79 | SSTR4 (0.44) | SSTR4MAPK1HTTEPHX1MEN1 | |
| SCHEMBL17154089 | 0.79 | MAPK1 (0.40) | SSTR4MAPK1HTTSMN1; SMN2MAPT | |
| SCHEMBL8128948 | 0.78 | LMNA (0.43) | SSTR4MAPK1HTTEPHX1SMN1; SMN2 | |
| SCHEMBL15722036 | 0.78 | MAPK1 (0.42) | SSTR4MAPK1HTTALDH1A1RAB9A | |
| SCHEMBL23343850 | 0.78 | SSTR4 (0.50) | SSTR4EPHX1SMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-10238677-B2 | Treatment of filarial diseases | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| WO-2016112317-A1 | TREATMENT OF FILARIAL DISEASES | ABBVIE INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-9245290-B2 | Caspase inhibitors and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-01-26 | — | — | US | disclosed |
| WO-2015138458-A1 | 4\"-0-SUBSTITUTED TYLOSIN A DERIVATIVES | ABBVIE INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20140011847-A1 | CASPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-01-09 | — | — | US | disclosed |
| US-8518942-B2 | Caspase inhibitors and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SSTR4 3594/4885MAPK1 1/4885HTT 1689/4885 |
| US-10238677-B2 | Treatment of filarial diseases | LTA, PPT1, LTA4H | SSTR4 3683/4885MAPK1 3950/4885HTT 342/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | SSTR4 3594/4885MAPK1 1/4885HTT 1689/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SSTR4 3572/4885MAPK1 1/4885HTT 1760/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | SSTR4 3594/4885MAPK1 1/4885HTT 1689/4885 |
| US-20140011847-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP6, CASP3, CASP2 | SSTR4 4675/4885MAPK1 2657/4885HTT 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.